Biologics for psoriatic arthritis: network meta-analysis in review.

Abstract

OBJECTIVE\nA review of network meta-analysis to assess efficacy and safety of biologics for the treatment of psoriatic arthritis (PsA).\n\n\nMATERIALS AND METHODS\nA systematic search was conducted on electronic databases to identify Bayesian meta-analysis reporting clinical parameters of efficacy, safety and cost-effectiveness of biologics that are approved for the treatment of PsA patients.\n\n\nRESULTS\nWe identified 19 studies and included them for review. There is insufficient statistical evidence to demonstrate clear differences in effectiveness between available biologic agents for PsA due to many differences in methods and clinical parameters reported in the studies. Old biologics are reported to be safe.\n\n\nCONCLUSIONS\nNew molecules approved for the treatment of PsA appear promising treatments but further comparative studies methodologically well-conducted are necessary. It is also necessary to follow strictly international recommendations to conduct NMA to better help physicians and decision-makers in making appropriate decisions.